| D007917 |
Leprostatic Agents |
Substances that suppress Mycobacterium leprae, ameliorate the clinical manifestations of leprosy, and/or reduce the incidence and severity of leprous reactions. |
Antileprotic Agents,Leprostatics,Agents, Antileprotic,Agents, Leprostatic |
|
| D007918 |
Leprosy |
A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid. |
Hansen's Disease,Hansen Disease |
|
| D009166 |
Mycobacterium leprae |
A species of gram-positive, aerobic bacteria that causes LEPROSY in man. Its organisms are generally arranged in clumps, rounded masses, or in groups of bacilli side by side. |
|
|
| D004359 |
Drug Therapy, Combination |
Therapy with two or more separate preparations given for a combined effect. |
Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D012293 |
Rifampin |
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) |
Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin |
|
| D014944 |
World Health Organization |
A specialized agency of the United Nations designed as a coordinating authority on international health work; its aim is to promote the attainment of the highest possible level of health by all peoples. |
Organization, World Health,WHO |
|
| D015440 |
Leprosy, Lepromatous |
A chronic communicable infection which is a principal or polar form of LEPROSY. This disorder is caused by MYCOBACTERIUM LEPRAE and produces diffuse granulomatous skin lesions in the form of nodules, macules, or papules. The peripheral nerves are involved symmetrically and neural sequelae occur in the advanced stage. |
Leprosy, Cutaneous,Leprosy, Nodular,Cutaneous Leprosies,Cutaneous Leprosy,Lepromatous Leprosies,Lepromatous Leprosy,Leprosies, Cutaneous,Leprosies, Lepromatous,Leprosies, Nodular,Nodular Leprosies,Nodular Leprosy |
|
| D015441 |
Leprosy, Tuberculoid |
A principal or polar form of LEPROSY in which the skin lesions are few and are sharply demarcated. Peripheral nerve involvement is pronounced and may be severe. Unlike lepromatous leprosy (LEPROSY, LEPROMATOUS), the lepromin test is positive. Tuberculoid leprosy is rarely a source of infection to others. |
Leprosy, Macular,Leprosy, Neural,Tuberculoid Leprosy,Leprosies, Macular,Leprosies, Neural,Leprosies, Tuberculoid,Macular Leprosies,Macular Leprosy,Neural Leprosies,Neural Leprosy,Tuberculoid Leprosies |
|
-transparent.png){kind=logo}
